Cheng AL - Search Results

1

IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation.

Hack SP, Spahn J, Chen M, Cheng AL, Kaseb A, Kudo M, Lee HC, Yopp A, Chow P, Qin S. Hack SP, et al. Among authors: cheng al. Future Oncol. 2020 May;16(15):975-989. doi: 10.2217/fon-2020-0162. Epub 2020 Apr 30. Future Oncol. 2020. PMID: 32352320

2

Prognostic value of multidrug resistance 1, glutathione-S-transferase-pi and p53 in advanced nasopharyngeal carcinoma treated with systemic chemotherapy.

Hsu CH, Chen CL, Hong RL, Chen KL, Lin JF, Cheng AL. Hsu CH, et al. Among authors: cheng al. Oncology. 2002;62(4):305-12. doi: 10.1159/000065061. Oncology. 2002. PMID: 12138237

3

Low-dose thalidomide treatment for advanced hepatocellular carcinoma.

Hsu C, Chen CN, Chen LT, Wu CY, Yang PM, Lai MY, Lee PH, Cheng AL. Hsu C, et al. Among authors: cheng al. Oncology. 2003;65(3):242-9. doi: 10.1159/000074477. Oncology. 2003. PMID: 14657598

4

Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.

Lu YS, Hsu C, Li CC, Kuo SH, Yeh KH, Yang CH, Hsu CH, Wu CY, Cheng AL. Lu YS, et al. Among authors: cheng al. Hepatogastroenterology. 2004 May-Jun;51(57):815-9. Hepatogastroenterology. 2004. PMID: 15143923 Clinical Trial.

5

Recent advances in non-surgical treatment for advanced hepatocellular carcinoma.

Hsu C, Cheng JC, Cheng AL. Hsu C, et al. Among authors: cheng al, cheng jc. J Formos Med Assoc. 2004 Jul;103(7):483-95. J Formos Med Assoc. 2004. PMID: 15318270 Review.

6

Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer.

Yeh KH, Lu YS, Hsu CH, Lin JF, Hsu C, Kuo SH, Li SJ, Cheng AL. Yeh KH, et al. Among authors: cheng al. Oncology. 2005;69(1):88-95. doi: 10.1159/000087304. Epub 2005 Aug 2. Oncology. 2005. PMID: 16088236 Clinical Trial.

7

Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial.

Lin CC, Hsu C, Hsu CH, Hsu WL, Cheng AL, Yang CH. Lin CC, et al. Among authors: cheng al. Invest New Drugs. 2007 Feb;25(1):77-84. doi: 10.1007/s10637-006-9004-9. Epub 2006 Aug 26. Invest New Drugs. 2007. PMID: 16937079 Clinical Trial.

8

Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.

Lin CC, Hsu CH, Huang CY, Cheng AL, Vogelzang NJ, Pu YS. Lin CC, et al. Among authors: cheng al. J Urol. 2007 Jan;177(1):84-9; discussion 89. doi: 10.1016/j.juro.2006.08.058. J Urol. 2007. PMID: 17162009 Clinical Trial.

9

A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer.

Lin CC, Cheng AL, Hsu CH, Lu YS, Hsu C, Yeh KH, Wu CY, Huang CS, Yang CH. Lin CC, et al. Among authors: cheng al. Anticancer Res. 2007 Jan-Feb;27(1B):641-5. Anticancer Res. 2007. PMID: 17348454 Free article. Clinical Trial.

10

Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: in vitro combined effects and a phase II trial.

Lin CC, Hsu CH, Hour TC, Cheng AL, Huang CY, Huang KH, Chen J, Pu YS. Lin CC, et al. Among authors: cheng al. Urol Oncol. 2007 May-Jun;25(3):207-13. doi: 10.1016/j.urolonc.2006.06.002. Urol Oncol. 2007. PMID: 17483017 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

823 results

Search Page

Filters